Galcanezumab - Eli Lilly

Drug Profile

Galcanezumab - Eli Lilly

Alternative Names: Emgality; LY-2951742

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Migraine
  • Phase III Cluster headache
  • Discontinued Musculoskeletal pain

Most Recent Events

  • 27 Jun 2018 Eli Lilly and Company expects the US FDA decision for galcanezumab for Migraine (Prevention)by the end of September 2018
  • 27 Jun 2018 Efficacy and adverse events data from a phase III trial in Cluster Headache released by Eli Lilly
  • 18 Jun 2018 Eli Lilly plans a phase III trial for Migraine (Treatment resistant) in August 2018 (NCT03559257)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top